Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01811277
Other study ID # SOX-S-1 BTC
Secondary ID
Status Recruiting
Phase Phase 2
First received March 11, 2013
Last updated March 13, 2013
Start date July 2010
Est. completion date July 2014

Study information

Verified date July 2010
Source Peking University
Contact Lin Shen, Prof.
Phone +86 10 88196175
Email lin100@medmail.com.cn
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is an exploratory, single-armed, open label study on the efficacy and safety of sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary system or periampullary cancer or pancreatic cancer patients. The primary endpoint is Objective response rate and secondary endpoint is progression free survival , overall survival ,1 year survival rate and safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Written Informed consent

- Male or female patients >=18 years old

- Histologically or cytologically confirmed diagnosis of adenocarcinoma

- No previous treatment is allowed including chemotherapy, radiotherapy,immunotherapy or others.

- In case the patient received adjuvant therapy before, enrollment is allowed if the adjuvant therapy does not contain L-OHP or S-1 and at the same time, the last day of chemotherapy is =180 days before screening.

- Target lesion more than 1cm in diameter by enhanced CT or MRI 21 days before enrollment

- The laboratory parameter meets the following criteria 7 days before enrollment

- Hemoglobin =90g/L

- Absolute neutrophil count=1.5×10^9/L, platelets 100×10^9/L;

- ALT and AST=2.5 ULN(in case of the patients with liver metastasis,ALT and AST=5.0 ULN)

- ALP =2.5 ULN (in case of the patients with liver metastasis,=5.0 ULN)

- Total Serum bilirubin =1.5 ULN

- Serum creatinine =1.0 ULN

- serum albumin(ALB)=30g/L;

- can tolerate oral drug administration;

- KPS =70

- Estimated survival =90 days

- Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of enrollment and must be willing to use adequate methods of contraception during the study and for 30 days after last study durg administration.

Exclusion Criteria:

- Known sensitivity to 5-HT3 antagonist and hypersensitivity to the other treatment agents including irinotecan, cisplatin and octreotide lar

- Any participation in trials simultaneously or 4 weeks before screening.

- 15 days prior to enrollment, received a blood transfusion, blood products and hematopoietic growth factors such as G-CSF.

- Undergone major surgery = 4 weeks prior to starting study drug or who have not recovered from side effects of such surgery.

- Uncontrolled severe diarrhea

- Uncontrolled active infection (fever =38 degrees due to infection)

- S-1 oral drug administration difficulty due to difficulty swallowing, complete or incomplete digestive tract obstruction, gastrointestinal active bleeding, perforation;

- severe hepatopathy including active hepatitis and hepatic cirrhosis, renal dysfunction, severe pulmonary diseases including interstitial pneumonia, pulmonary fibrosis and severe pulmonary emphysema, uncontrolled diabetes, hypertension and other chronic systematic diseases.

- Chronic treatment with steroids.(In case of the patients with short-term use of steroids, the enrollment is permitted if the administration is stopped 2 weeks before screening.)

- confirmed or suspected CNS metastasis

- the history of peripheral nervous system impairment, obvious mental disorder or CNS impairment

- clinically significant heart disease, including congestive heart failure, symptomatic coronal heart disease, arrythmia uncontrolled by medication and acute myocardial infarction or cardiac insufficiency within 6 months before screening

- Drainage of pleural effusion, peritoneal effusion and pericardial effusion

- pregnant women or women in lactation period

- Fertile male or women of child-bearing potential refuse to take highly effective methods of birth control

- Incidence of other second primary malignant tumors within 5 years, except for cured basal cell carcinoma and cervical carcinoma in situ.

- patients of legal incapacity or who have the potential of influence the whole trial due to medical or ethic reasons.

- Other patients who are not eligible to the trial under investigators' discretion

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
SOX sequential S-1
4-6 cycles SOX followed by S-1 monotherapy until disease progression S-1: 40~60mg bid,po, d1~14 (S-1:BSA <1.25m2, 40mg bid, 1.25m2=BSA=1.5m2,50mg bid, BSA>1.5m2, 60mg bid) oxaliplatin:130mg/m2,iv drip for 2h,d1

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Peking University Taiho Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate for SOX sequential S-1 The primary endpoint is objective response rate,which equals CR+PR. 1 years No
Secondary Overall Survival OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost 2 years No
Secondary progression free survival PFS means that from the first dose of treatment drug to disease progression or death or lost, the follow-up visit will be performed every 6 weeks till progression or death or lost 1 year No
Secondary 1 year survival rate the follow-up visit of survival will be performed every 3 months till 1 year 1 year No
Secondary Number of Participants with Adverse Events as a Measure of Safety and Tolerability participants will be followed for the duration of hospital stay, an expected average of 3 weeks 2 years Yes
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study